Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 5;58(1):1-9.
doi: 10.14744/SEMB.2024.87864. eCollection 2024.

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Yucel Yankol  1 , Oswaldo Aguirre  1 , Luis A Fernandez  1
Affiliations
Review

Impact of Living Donor Liver Transplantation on the Improvement of Hepatocellular Carcinoma Treatment

Yucel Yankol et al. Sisli Etfal Hastan Tip Bul. .

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, with increasing incidence. There are different treatment options, but only 30%-40% of HCC cases are diagnosed at an early stage for curative treatment. With the implementation of Milan Criteria for liver transplantation (LT) in HCC cases and its use for organ allocation with successful outcomes, LT has become an optimal treatment. Seeking new criteria for LT and developing updated algorithms for HCC treatment has become a hot topic nowadays. With the experience in living donor liver transplantation (LDLT), especially in Asian countries, LDLT was established and adopted with different criteria for HCC treatment, especially including criteria beyond Milan's size and number of tumors. Living donor grafts are uniquely different than deceased donor grafts as they are not considered a public resource. A living donor graft is rather a private gift intended for a specific recipient. Living donor livers are not limited by organ allocation systems, and this significant advantage of LDLT has opened new frontiers in the treatment of HCC. Improvements in LDLT have had remarkable parallel effects in the successful treatment of HCC as supported by a growing body of literature in the past decade.

Keywords: Criteria; hepatocellular carcinoma; living donor liver transplant.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. - PMC - PubMed
    1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9. - PubMed
    1. Bruix J, LIovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24. - PubMed
    1. Park MS, Lee KW, Kim H, Choi YR, Hong G, Yi NJ, et al. Primary living-donor liver transplantation is not the optimal treatment choice in patients with early hepatocellular carcinoma with poor tumor biology. Transplant Proc. 2017;49:1103–8. - PubMed
    1. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, et al. Orthotopic homotransplantation of the human liver. Ann Surg. 1968;168:392–415. - PMC - PubMed

LinkOut - more resources